Pharma to EU officials: We need ‘contingency’ supply plans in case of ‘Grexit’

Tracy Staton Drugmakers are raising an alarm about shortages in Greece as the possibility of a "Grexit" looms. That "worst-case scenario" could put supplies in peril, ...

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

Carly Helfand Horizon Pharma isn't exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping ...

How well paid are pharma execs? Best in healthcare, survey shows

Tracy Staton How does pharma executive pay compare with the rest of healthcare? Forbes columnist Dan Munro decided to find out–and the answer is that drugmakers pay their top ...

Bavarian Nordic quashes talk of interest in a Big Pharma buyout

Nick Paul Taylor Bavarian Nordic has downplayed its interest in becoming the latest European biotech to be scooped up by a deep-pocketed suitor. The vaccine player has regained some ...

ArGEN-X pairs up with Leo Pharma in a $116M dermatology deal

Damian Garde The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $ 116 ...

Endo sews up $9.2B financing for Par Pharma buyout

Carly Helfand Earlier this week, Endo inked a pact to nab Par Pharmaceutical for $ 8 billion. But to do that, it'll need a loan, and it's agreed to a $ 9.275 billion loan ...

When it comes to pharma corporate branding, Biogen is onto something

Carly Helfand Pharma may have something to learn from Biogen's recent move to lop the "Idec" off its name. It's not enough to rely on big drug brands and product ...

Pharma hikes prices on all sorts of meds, but hit diabetes hardest: Bloomberg

Tracy Staton Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years, Bloomberg reports. Once again, the usual suspects ...

J&J, Novartis lead pharma companies by market cap

Carly Helfand Which Big Pharma companies have the biggest market caps in the industry? The Motley Fool has a breakdown of the top 10, but we'll give you a hint: The list ...

Pharma wanted pricey orphan meds, and now it’s got ’em in record numbers

Carly Helfand New drug approvals were up last year, and orphan drug approvals were no exception. But by just how much did they climb? The FDA Law Blog has done some digging ...

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets

EJ Lane FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth quarter earnings calls to explain what C-suite executives are ...

Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit’s spinoff

Carly Helfand It's new year, new company for Reckitt Benckiser's pharma unit, spun off into Indivior last week. And while 2015 might not be the easiest for the newly minted ...
Page 3 of 1712345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS